G1t38 Free Base Uses, Dosage, Side Effects and more
G1t38 Free Base is under investigation in clinical trial NCT02983071 (G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-positive, Her2-negative Locally Advanced or Metastatic Breast Cancer).
| Trade Name | G1t38 Free Base |
| Generic | Lerociclib |
| Lerociclib Other Names | G1t38 free base, Lerociclib |
| Type | |
| Formula | C26H34N8O |
| Weight | Average: 474.613 Monoisotopic: 474.285557747 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
